International Journal of Cancer最新文献

{"title":"Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT-OES-1 Trial","authors":"Charlène J. van der Zijden,&nbsp;Tamara J. Huizer,&nbsp;Ben M. Eyck,&nbsp;Ate van der Gaast,&nbsp;Leni van Doorn,&nbsp;Marjolein Y. V. Homs,&nbsp;J. Jan B. van Lanschot,&nbsp;Joost J. M. E. Nuyttens,&nbsp;Lindsey Oudijk,&nbsp;Manon C. W. Spaander,&nbsp;Bas P. L. Wijnhoven,&nbsp;Bianca Mostert,&nbsp;Sjoerd M. Lagarde","doi":"10.1002/ijc.70594","DOIUrl":"10.1002/ijc.70594","url":null,"abstract":"<p>Chemotherapy (FLOT) and chemoradiotherapy (CROSS) are both effective as neoadjuvant regimens for esophageal/junctional cancer. Total Neoadjuvant Therapy (TNT) aims to increase efficacy by combining chemotherapy with chemoradiotherapy. This study aimed to evaluate the feasibility and safety of TNT FLOT-CROSS. Patients with histologically proven esophageal/junctional adenocarcinoma with oligometastases (maximum four lesions in maximum two organs) were included. Treatment consisted of four cycles of FLOT followed by response evaluation (CT-scan). Patients without disease progression proceeded to CROSS, followed by response evaluation (CT-scan, endoscopy with biopsies and endoscopic ultrasonography with fine-needle aspiration on indication). Primary endpoint was the safety and tolerability of TNT FLOT-CROSS. Secondary endpoints included progression-free survival (PFS), disease control rate (DCR), quality of life (QoL) using QLQ-C30 and QLQ-OG25, toxicity and the proportion of patients proceeding to local therapy. Twenty patients were included of whom 16 (80%) had a single metastatic lesion. Median follow-up was 47.9 months (95% CI 32.8–63.1). Fifteen patients (75%) completed TNT FLOT-CROSS. FLOT came with manageable, expected toxicity, and all patients without progression were able to start and complete CROSS. No grade 3–5 toxicities occurred during CROSS. After TNT FLOT-CROSS, two patients underwent surgery. The 1- and 2-year PFS were 40% and 13%, respectively. Three months after TNT FLOT-CROSS completion, DCR was 55%. Dysphagia scores significantly decreased over time, while fatigue significantly increased. Sequencing TNT FLOT-CROSS in patients with oligometastatic esophageal adenocarcinoma is feasible and comes with manageable toxicity and promising efficacy, with a 1-year progression free survival of 40%.</p><p><b>Trial Registration:</b> Dutch trial register, NL9269</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"159 10","pages":"2552-2561"},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.70594","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changing the History of Science—An Editorial Perspective on Critical Developments in Current Citation Practice, “Forgetting” the Pioneers of Scientific Discoveries","authors":"Heike Allgayer,&nbsp;Petra Boukamp","doi":"10.1002/ijc.70685","DOIUrl":"10.1002/ijc.70685","url":null,"abstract":"&lt;p&gt;Sixty years have passed since the &lt;i&gt;International Journal of Cancer&lt;/i&gt; launched its first publication in 1966, and we would like to take this opportunity to congratulate the Journal on this jubilee. Tremendous developments in science and medicine have been seen and reported during the history that passed since then, and many changes have taken place in the way how we observe, conduct, publish, and rank the importance of science. Many of these changes have increased our knowledge immensely and led to iconic changes and improvements for humankind, for example for the diagnosis, treatment, or the prevention of cancer.&lt;/p&gt;&lt;p&gt;However, some developments in the more and more professionalized world of publishing and selling research have also given rise to concern. In this Editorial, we would like to bring attention to a particular development in publication practice that we consider worrisome, which seems to become an increasing trend within habits of acknowledging and citing, or rather not citing, earlier pioneering references within scientific original publications and reviews. Specifically, during the last years it has become evident that a growing number of publications tend to cite mainly recent publications in the field and particularly recent reviews that, themselves, frequently rely on citations of the latest previous reviews. Thereby, they tend to ignore and miss seminal papers that have been published in the past by the scientific pioneers in the respective field.&lt;/p&gt;&lt;p&gt;As an example, in a pioneering phase starting at the end of the 1980s and lasting through the 1990s, many pioneers in the field discovered, and described in utmost detail, the essential molecular function of tumor-associated proteases in all major steps of the metastatic cascade of cancer cells. Certainly, also the &lt;i&gt;International Journal of Cancer&lt;/i&gt; took its part in the early publications on this topic. Some of the proteases, especially the urokinase (u-PA) system with u-PA, the receptor u-PAR, and the inhibitor PAI-1, were shown at this time to be highly relevant, not only for migration, invasion, metastasis, and associated molecular signaling, but also for patient survival, prognosis, minimal residual disease, or tumor recurrence. This knowledge was driven by many protagonists in Europe, for example, the Finsen Laboratory Denmark, basic, translational and clinical research groups in Germany, Italy, the Netherlands, and further European countries, as well as groups in the United States (e.g., [&lt;span&gt;1-26&lt;/span&gt;], and briefly reviewed again recently in [&lt;span&gt;27&lt;/span&gt;]). This list of publications is by far not complete and many further publications by these and further groups were published at these early times. While the u-PA/u-PA-R system seems to regain international attention at present, in many recent publications on this topic (e.g., [&lt;span&gt;28, 29&lt;/span&gt;]), however, the many pioneering pieces of work of the early phase mentioned above are rather ignored, and acc","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"159 10","pages":"2377-2380"},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.70685","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study","authors":"Joyce Meijer,&nbsp;Nienke Hermanns,&nbsp;Rhodé Bijlsma,&nbsp;Hedwig M. Blommestein,&nbsp;Desiree H. J. G. van den Bongard,&nbsp;Thijs van Dalen,&nbsp;Paul J. van Diest,&nbsp;Caroline A. Drukker,&nbsp;Cristina Guerrero Paez,&nbsp;Aafke H. Honkoop,&nbsp;Agnes Jager,&nbsp;Linetta B. Koppert,&nbsp;Sabine C. Linn,&nbsp;Marissa C. van Maaren,&nbsp;Ester J. Siemerink,&nbsp;Laura J. van ’t,&nbsp;José H. Volders,&nbsp;Marie Jeanne Vrancken Peeters,&nbsp;Sabine Siesling","doi":"10.1002/ijc.70571","DOIUrl":"10.1002/ijc.70571","url":null,"abstract":"<p>This study examined gene expression profile (GEP) use in relation to reimbursement policies and chemotherapy administration, both for patients with and without GEP indication. Women aged ≥ 18–69 years and diagnosed with early-stage breast cancer between January 2011 and June 2024 were selected from the Netherlands Cancer Registry. GEP use in relation to reimbursement policies and GEP result in relation to chemotherapy administration was analysed using flowcharts and a trend line. For patients with GEP indication, logistic regression analyses were conducted to determine if the reimbursement periods influenced the GEP use, and GEP use was analysed per region in the Netherlands and incidence year using trend lines. In total, 138,765 patients were included. Among 17,525 patients with GEP indication, proportions of patients who received a GEP were higher during retrospective reimbursement (25%) and publicly known reimbursement (37%) compared with no reimbursement (9%) and differed across regions in the Netherlands. Proportions of patients who did not receive chemotherapy were higher for patients who had a low-risk MammaPrint (93%) or Oncotype DX (97%) result compared with patients who had a high-risk MammaPrint (17%) or Oncotype DX (15%) result. Among 13,003 patients with GEP indication who did not receive GEP, 52% did receive chemotherapy. Approximately one-third of patients who met GEP criteria and were eligible for publicly known reimbursement received a GEP. Appropriate follow-up steps and further research seem required to analyse reasons for not ordering a GEP in times of reimbursement, since GEP results help chemotherapy decision-making.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"159 10","pages":"2485-2497"},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.70571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148161057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study","authors":"Jinxia Wang,&nbsp;Ping Qi,&nbsp;Jinhua Li,&nbsp;Na Wang,&nbsp;Caihong Fu,&nbsp;Lixin Liu,&nbsp;Shuping Li,&nbsp;Xiao Li,&nbsp;Xiaoming Hou,&nbsp;Hui Qiao","doi":"10.1002/ijc.70617","DOIUrl":"10.1002/ijc.70617","url":null,"abstract":"<p>While third-generation EGFR tyrosine kinase inhibitors (TKIs) improve outcomes in EGFR-mutant NSCLC, optimal selection between these agents remains uncertain. This real-world study compares the efficacy and safety of aumolertinib with those of osimertinib in the first-line treatment setting. We retrospectively analyzed 109 EGFR-mutant (exon 19del/L858R) NSCLC patients treated with first-line aumolertinib (<i>n</i> = 53) or osimertinib (<i>n</i> = 56) across four tertiary hospitals (2016–2023). The primary end points included progression-free survival (PFS) and safety; secondary end points encompassed overall survival (OS), objective response rate (ORR), and predictive biomarker identification through subgroup analyses. Aumolertinib demonstrated superior median PFS compared to osimertinib (34.4 vs. 26.9 months; HR 0.52, 95% CI 0.29–0.92, <i>p</i> = 0.031), with comparable OS (HR 0.76, 95% CI 0.27–2.15, <i>p</i> = 0.60). No significant differences emerged in primary lesion ORR (33.96%, 18/53 vs. 42.86%, 24/56) or adverse event (AE) rates (37.7%, 20/53 vs. 39.3%, 22/56). Subgroup analyses confirmed enhanced PFS benefit with aumolertinib in exon 19del-mutant (HR 0.43, 95% CI 0.21–0.87, <i>p</i> = 0.02) and co-mutation-negative (HR 0.53, 95% CI 0.25–1.14, <i>p</i> = 0.08) populations. Subgroup analysis identified age &lt; 65 years (HR 0.46, 95% CI 0.22–0.99, <i>p</i> = 0.046), brain metastases (HR 0.24, 95% CI 0.09–0.66, <i>p</i> = 0.006), and exon 19del status (HR 0.43, 95% CI 0.2–0.89, <i>p</i> = 0.023) as independent PFS predictors. Regarding safety, aumolertinib showed a lower overall incidence of liver dysfunction compared to osimertinib (9.43%, 5/53 vs. 14.29%, 8/56), with Grade ≥ 3 events being rare (1.89%, 1/53). Given that liver function is a critical determinant of prognosis, the manageable hepatic safety profile of aumolertinib supports its long-term clinical utility. Our study demonstrated a clinically meaningful PFS advantage of aumolertinib over osimertinib in treatment-naïve EGFR-mutant NSCLC, particularly for exon 19del-driven and co-mutation-negative disease, while maintaining equivalent safety. These findings provide valuable real-world evidence supporting the use of aumolertinib as a first-line therapy, contributing to the optimization of treatment selection and AE management. While these subgroup-specific results offer hypothesis-generating insights into potential biomarkers for therapeutic individualization, these preliminary findings require further validation in larger, prospective cohorts.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"159 10","pages":"2575-2584"},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.70617","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RETRACTION: MAEL Expression Links Epithelial-Mesenchymal Transition and Stem Cell Properties in Colorectal Cancer.","authors":"","doi":"10.1002/ijc.70739","DOIUrl":"https://doi.org/10.1002/ijc.70739","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer.","authors":"Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T Jones, Grace Gard, Sue-Anne McLachlan, Jeanne Tie, Lucy Gately, Peter Gibbs","doi":"10.1002/ijc.70754","DOIUrl":"https://doi.org/10.1002/ijc.70754","url":null,"abstract":"<p><p>Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5-fluorouracil (5-FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD), we identified patients with Stage III colon cancer diagnosed between 1 January 2006 and 31 December 2023. Concomitant PPI use during adjuvant chemotherapy was determined by chart review. We evaluated the prevalence of PPI use with fluoropyrimidine-containing adjuvant therapy and its association with recurrence-free survival (RFS) and overall survival (OS). A total of 459 patients were included as follows: 63 (14%) received 5-FU alone, 115 (25%) capecitabine alone, 148 (32%) FOLFOX and 133 (29%) CAPOX. High-risk disease (T4 and/or N2) was present in 203 patients (44%). Overall, 142 patients (31%) received a PPI during adjuvant chemotherapy, with similar rates across treatment groups (p = 0.952). Formal interaction testing did not demonstrate significant heterogeneity of PPI effect across treatment regimens (RFS: LR test p = 0.615; OS: LR test p = 0.143). However, in high-risk patients receiving CAPOX, PPI use was associated with reduced RFS (HR 3.07, 95% CI 1.38-6.84, p = 0.006) and OS (HR 4.11, 95% CI 1.44-11.74, p = 0.008). No impact was observed with capecitabine monotherapy, 5-FU, or FOLFOX. Concomitant PPI use is common in Australian patients with Stage III colon cancer. While formal interaction testing did not reach statistical significance, PPI use was associated with inferior survival outcomes in high-risk patients receiving CAPOX.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149014903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.","authors":"Nadira R Querido, Martijn J L Bours, Liselot Valkenburg-van Iersel, Antoinetta J M Beijers, Stephanie O Breukink, Maryska L G Janssen-Heijnen, Eric T P Keulen, Joop L M Konsten, Judith de Vos-Geelen, Matty P Weijenberg, Colinda C J M Simons","doi":"10.1002/ijc.70745","DOIUrl":"https://doi.org/10.1002/ijc.70745","url":null,"abstract":"<p><p>Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially long-term consequence of oxaliplatin-based chemotherapy for colorectal cancer (CRC). Oxaliplatin dosing is based on body surface area (BSA), but lean body mass (LBM) may influence susceptibility to long-term CIPN. We examined associations between oxaliplatin treatment and CIPN up to 2 years post-treatment and whether LBM modified these associations. In a prospective cohort, we analysed 106 stage II-III CRC patients treated with adjuvant CAPOX. Data on oxaliplatin treatment were obtained from medical records. CIPN during treatment was graded with the CTCAE, and patient-reported CIPN was assessed by the EORTC QLQ-CIPN20 questionnaire at diagnosis and at 6 weeks and 6, 12, and 24 months post-treatment. LBM was derived from diagnostic CT scans, and sarcopenia was defined using sex-specific skeletal muscle index cut-offs. Longitudinal associations were analysed through confounder-adjusted linear mixed models. Effect modification by LBM and sarcopenia was examined by stratified analyses (median-split) and interaction tests. Higher cumulative oxaliplatin dose (β per 0.5 SD 2.91, 95% CI 1.22-4.59), relative oxaliplatin dose intensity (3.15, 1.2-5.25), and initial dose (2.21, 0.46-3.95) were longitudinally associated with higher CIPN summary scores. Patients with grade 2/3 CIPN had higher post-treatment CIPN scores (5.82; 0.63-11.01) than those with grade 1. Associations were generally stronger in patients with low LBM or sarcopenia, although interaction tests were not statistically significant. In conclusion, higher oxaliplatin exposure and CIPN during treatment were associated with greater long-term CIPN burden. Patients with low LBM or sarcopenia may be particularly vulnerable under current BSA-based dosing.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long-Term Survival Outcomes.","authors":"Thierry Alcindor, James Tankel, Pierre-Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools-Lartigue, Sophie Camilleri-Broet, Lorenzo Ferri","doi":"10.1002/ijc.70749","DOIUrl":"https://doi.org/10.1002/ijc.70749","url":null,"abstract":"<p><p>Long-term survival data for patients with locally advanced gastro-esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long-term disease-free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with docetaxel/cisplatin/5-fluorouracil). The 50 patients included in the study were treated with 4 neoadjuvant cycles of aDCF followed by an en-bloc transthoracic resection after which 4 additional adjuvant cycles were planned to be given. An exploratory analysis of patients achieving major pathological response (MPR) was also performed. There were 50 patients included in the survival analysis. Clinical disease burden was high (cT3 44/50, 88%, N+ 31/50, 62%) with 49/50 (98%) completing neoadjuvant aDCF. All patients proceeded to surgery with MPR found in 9/50 (18%) patients. The median follow-up for the cohort was 71.5 months (range 43-105) with an estimated median DFS and OS of 61.0 months (95% CI not met) and 77.0 months (95% CI not met) corresponding to a 5-year DFS and OS of 50.0% and 60.0%. For patients with MPR, 5-year DFS and OS were 100%. There were no new safety signals. We conclude that aDCF is a feasible and novel regimen for patients with locally advanced esophagogastric adenocarcinoma providing durable survival outcomes. These outcomes seem enhanced among patients with MPR.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148981724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Incidence Rates of Anogenital Cancers in Costa Rica, 1996-2022.","authors":"Loretto J Carvajal, Jaimie Z Shing, Juan Carlos Vanegas, Rebeca Ocampo, Emmanuel González, Diego Guillén, Carolina Porras, Rolando Herrero, Alejandro Calderón, Meredith S Shiels, Rachel Slimovitch, Mónica S Sierra, Joel M Palefsky, Cameron Haas, Danping Liu, Aimée R Kreimer, Romain Fantin","doi":"10.1002/ijc.70664","DOIUrl":"https://doi.org/10.1002/ijc.70664","url":null,"abstract":"<p><p>Human papillomavirus (HPV) is the necessary cause of cervical cancer and responsible for ~90% of anal, 78% of vaginal, 50% of penile, and 25% of vulvar cancers. In Costa Rica (CR), few studies have examined incidence trends of these cancers. We assessed age-standardized incidence rates (ASIRs) and trends of invasive anogenital cancers. Incidence data were obtained from the CR National Registry of Tumors and population estimates from the National Institute of Statistics and Census. ASIRs (1960-Segi World population) were calculated using Surveillance, Epidemiology, and End Results (SEER)*Stat, and trends and annual percent changes (APCs) using Joinpoint regression. During 1996-2022, 10,022 invasive anogenital cancer cases were included in the analysis; of which 8122 (81.0%) were cervical. Cervical cancer incidence declined significantly (APC: -3.2%, 95% confidence interval [CI]: -3.9, -2.5). Vaginal cancer showed a non-statistically significant increase (APC: 0.8%, 95% CI: -1.6, 4.1), while vulvar and penile cancers presented a non-statistically significant decrease (APC: -0.8, 95% CI: -1.9, 0.4, and -0.8, 95% CI: -2.1, 1.0, respectively). Anal cancer incidence remained stable (APC: 0.2, 95% CI: -0.9, 1.8) and was 1.4 times higher in females than males (5.3 and 3.7 per million, respectively). In males, penile cancer incidence was 3-times higher than anal cancer (10.9 vs. 3.7 per million). Non-cervical anogenital cancers were rare and showed varying trends. Cervical cancer remains a public health concern in CR, requiring stronger prevention. Research on vaccine-covered HPV genotypes and continued surveillance of anogenital cancers are needed to assess prevention impact.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"FHL₂ Expression by Cancer-Associated Fibroblasts Promotes Metastasis and Angiogenesis in Lung Adenocarcinoma\".","authors":"","doi":"10.1002/ijc.70597","DOIUrl":"10.1002/ijc.70597","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":"1570-1571"},"PeriodicalIF":4.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13397200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148248137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}